The DDX11‐AS1/DNMT1/LATS2 pathway could serve as an oncogenic element in hepatocarcinogenesis, presenting a promising avenue for therapeutic intervention in treating HCC [48]. This evidence concerns the gene DDX11 and hepatocellular carcinoma.